Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 6380

1.

A one-two punch against prostate cancer.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2014 Mar;26(1):8. No abstract available.

PMID:
24937853
[PubMed - indexed for MEDLINE]
2.

[III. Prostate cancer].

Takehara K, Hakariya T, Sakai H.

Gan To Kagaku Ryoho. 2014 Jan;41(1):47-9. Japanese. No abstract available.

PMID:
24796022
[PubMed - indexed for MEDLINE]
3.

[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].

Boissier E, Loriot Y, Vignot S, Massard C.

Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French.

PMID:
24793632
[PubMed - indexed for MEDLINE]
4.

Bone health care for patients with prostate cancer receiving androgen deprivation therapy.

Tsang DS, Alibhai SM.

Hosp Pract (1995). 2014 Apr;42(2):89-102. doi: 10.3810/hp.2014.04.1107. Review.

PMID:
24769788
[PubMed - indexed for MEDLINE]
5.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM.

Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.

PMID:
24759320
[PubMed - indexed for MEDLINE]
6.

Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.

Shiota M, Yokomizo A, Takeuchi A, Itsumi M, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Prostate. 2014 Jun;74(9):959-69. doi: 10.1002/pros.22813. Epub 2014 Apr 17.

PMID:
24740858
[PubMed - indexed for MEDLINE]
7.

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.

Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR.

Lancet Oncol. 2014 May;15(6):592-600. doi: 10.1016/S1470-2045(14)70129-9. Epub 2014 Apr 14.

PMID:
24739897
[PubMed - indexed for MEDLINE]
8.

Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study.

Lycken M, Garmo H, Adolfsson J, Stattin P, Holmberg L, Bill-Axelson A.

Eur J Cancer. 2014 Jul;50(10):1789-98. doi: 10.1016/j.ejca.2014.03.279. Epub 2014 Apr 12.

PMID:
24736041
[PubMed - indexed for MEDLINE]
9.

Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks.

Nomiya T, Tsuji H, Maruyama K, Toyama S, Suzuki H, Akakura K, Shimazaki J, Nemoto K, Kamada T, Tsujii H; Working Group for Genitourinary Tumors.

Br J Cancer. 2014 May 13;110(10):2389-95. doi: 10.1038/bjc.2014.191. Epub 2014 Apr 10.

PMID:
24722181
[PubMed - indexed for MEDLINE]
10.

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.

Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, Horvath LG.

Br J Cancer. 2014 May 13;110(10):2462-71. doi: 10.1038/bjc.2014.181. Epub 2014 Apr 8.

PMID:
24714754
[PubMed - indexed for MEDLINE]
11.

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.

Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3.

PMID:
24703899
[PubMed - indexed for MEDLINE]
Free Article
12.

Re: The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.

Griebling TL.

J Urol. 2014 Apr;191(4):1056. doi: 10.1016/j.juro.2014.01.058. Epub 2014 Jan 17. No abstract available.

PMID:
24703136
[PubMed - indexed for MEDLINE]
13.

Re: Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.

Taneja SS.

J Urol. 2014 Apr;191(4):985. doi: 10.1016/j.juro.2014.01.077. Epub 2014 Jan 17. No abstract available.

PMID:
24703120
[PubMed - indexed for MEDLINE]
14.

Oncological outcomes of hormonal therapy with a gonadotropin-releasing hormone agonist combined with a steroidal or non-steroidal antiandrogen in patients with prostate cancer.

Igawa T, Tsurusaki T, Nomata K, Hayashi M, Furukawa M, Sakai H.

Anticancer Res. 2014 Apr;34(4):1983-8.

PMID:
24692735
[PubMed - indexed for MEDLINE]
15.

Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.

[No authors listed]

Prescrire Int. 2014 Feb;23(146):40-1.

PMID:
24669383
[PubMed - indexed for MEDLINE]
16.

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.

Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.

Prostate. 2014 Jun;74(8):820-8. doi: 10.1002/pros.22788. Epub 2014 Mar 26.

PMID:
24668612
[PubMed - indexed for MEDLINE]
17.

Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK.

J Clin Oncol. 2014 May 1;32(13):1324-30. doi: 10.1200/JCO.2013.52.5782. Epub 2014 Mar 17.

PMID:
24638009
[PubMed - indexed for MEDLINE]
18.

Steroid receptors aplenty in prostate cancer.

Sharifi N.

N Engl J Med. 2014 Mar 6;370(10):970-1. doi: 10.1056/NEJMcibr1315706. No abstract available.

PMID:
24597872
[PubMed - indexed for MEDLINE]
19.

Radical prostatectomy or watchful waiting in early prostate cancer.

Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Spångberg A, Andrén O, Palmgren J, Steineck G, Adami HO, Johansson JE.

N Engl J Med. 2014 Mar 6;370(10):932-42. doi: 10.1056/NEJMoa1311593.

PMID:
24597866
[PubMed - indexed for MEDLINE]
20.

[Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)].

Kitamura Y, Okuno H, Sakura Y, Manabe Y, Masuda N, Ito H, Mishina M, Taoka R, Terai A, Sugimoto M, Kakehi Y.

Hinyokika Kiyo. 2014 Jan;60(1):17-23. Japanese.

PMID:
24594768
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk